submit to the journals

Asthma Journal Articles, Videos And Insights

Asthma: FEATURED Articles

flipper_slider

Asthma: INSIGHTS

The touchRESPIRATORY website provides a selection of resources to inform clinicians and patients about the latest developments in the field. The following are quick, non peer-reviewed, opinion-based updates addressing current trends and opinion on the most recent advances in the area of respiratory medicine:

Insight
Highlights from the ATS International Congress 2018—Focus on Asthma Alex Lowe, Senior Medical Writer, Touch Medical Media, UK
Abraham Choong, Account Director and Advisory Editor, Touch Medical Media, UK
Insights into clinical trials optimizing asthma treatment presented at American Thoracic Society International Congress, San Diego, CA, US, May 18–23, 2018
Insight
Highlights from the ERS International Congress 2017: focus on asthma Katrina Mountfort, Senior Medical Writer, Touch Medical Media, UK
Matthew Goodwin, Respiratory Business Unit Director, Touch Medical Media, UK

Insight
Chronic insomnia is a risk factor for asthma in adults Katrina Mountfort, Senior Medical Writer, Touch Medical Media, UK
Matthew Goodwin, Respiratory Business Unit Director, Touch Medical Media, UK
Insights into the Nord-Trøndelag Health Study (HUNT), discussed at the ATS Annual Meeting, Washington DC, May 19–24, 2017
Insight
New data from the WINDWARD clinical trial program on benralizumab in severe asthma Katrina Mountfort, Senior Medical Writer, Touch Medical Media, UK
Andrew Potter, Respiratory Account Director, Touch Medical Media, UK
Insights into the WINDWARD clinical trial program, presented and discussed at the ATS Annual Meeting, Washington DC, May 19–24, 2017

Asthma: FEATURED VIDEOS

Editor's choice

Nicola A Hanania (Baylor College of Medicine, TX, US) is a valued member of our Editorial Board for US Respiratory & Pulmonary Diseases. Here he discusses with us the background and findings of his presentation entitled: What Symptomatic Patients with Asthma and Chronic Obstructive Pulmonary Disease (COPD) Find Important in Their Maintenance Inhaler Therapy: A Focus Group Study (abstract available here). Questions 1. Tell us a little about the Focus Group Study poster you are presenting tomorrow (0:11) View Part 1 here. View Part 2 here. Speaker disclosure: Nicola A Hanania has received honoraria for serving on advisory boards or as a consultant for Boehringer Ingelheim, GlaxoSmithKline, AstraZeneca, Novartis, and Sanofi/Regeneron. His institution has received research grant support on his behalf from Boehringer Ingelheim, AstraZeneca, Roche, and GlaxoSmithKline. Filmed at the American Thoracic Society (ATS) International Conference 2018, San Diego, CA, US, May 2018.
Linda Rogers (Icahn School of Medicine at Mount Sinai, New York, NY, US) discusses the background and findings of her presentation entitled: A Real World, Single Center Experience of Treatment of Severe Eosinophilic Asthma with IL-5 Antagonists; Mepolizumab and Reslizumab (abstract available here). Questions 1. Why is the treatment of eosinophilic asthma so challenging? (0:12) 2. What is the rationale for using interleukin 5 (IL-5) antagonists in patients with severe eosinophilic asthma? (0:43) 3. Could you tell us about your recent study investigating mepolizumab and reslizumab? (1:33) 4. Why do you think some patients who failed to respond to mepolizumab subsequently responded to reslizumab? (2:38) 5. What further studies are needed to optimise the use of these agents? (3:14) Speaker disclosure: Linda Rogers has nothing to disclose in relation to this video interview. Filmed at the American Thoracic Society (ATS) International Conference 2018, San Diego, CA, US, May 2018.

Asthma: Latest Videos

Video List based on Category on Node Page

Latest Videos

Nicola A Hanania (Baylor College of Medicine, TX, US) is a valued member of our Editorial Board for US Respiratory & Pulmonary Diseases. Here he discusses with us the background and findings of his presentation entitled: What Symptomatic Patients with Asthma and Chronic Obstructive Pulmonary...
Nicola A Hanania (Baylor College of Medicine, TX, US) is a valued member of our Editorial Board for US Respiratory & Pulmonary Diseases. He describes how inhalers in asthma and COPD are often misused and this issue can be avoided. He also considers factors that affect adherence with inhaler...
Nicola A Hanania (Baylor College of Medicine, TX, US) is a valued member of our Editorial Board for US Respiratory & Pulmonary Diseases. He discusses the different types of inhaler systems available for asthma and COPD, recommendations regarding these different delivery platforms and factors...
Linda Rogers (Icahn School of Medicine at Mount Sinai, New York, NY, US) discusses the background and findings of her presentation entitled: A Real World, Single Center Experience of Treatment of Severe Eosinophilic Asthma with IL-5 Antagonists; Mepolizumab and Reslizumab (abstract available...
Nicola Hanania talks to us about recent progress in profiling type 2 immune response-driven asthma and emerging data on on therapies targeting Interleukin (IL)-4, IL-5 and IL-13 in severe asthma. Part 2 of 2. 1. What recent progress has been made in profiling type 2 immune response-driven...
Nicola Hanania talks to us about precision medicine and the use of biomarkers in severe asthma. Part 1 of 2. 1. Why is there a need for precision medicine in severe asthma? (0:06) 2. What are the most promising biomarkers for predicting treatment response in asthma? (0:39) 3. How are...

LATEST TWEETS

Conference Highlights